Lilly Sepsis Trial Prompts Biotech-Style Jump In Second Quarter

Wall Street's enthusiastic response to Lilly's potential sepsis therapy may represent the triumph of biotechnology - at least in terms of investor approaches to pharmaceutical stock valuations.